GlobeNewsWire
03 Jun 2026, 11:40 UTC · 2h ago
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Search tags
GlobeNewsWire
03 Jun 2026, 11:40 UTC · 2h ago
Search tags
Story key points
3 claims · impact-rated
ResMed (NYSE: RMD) has acquired Noctrix Health in a transaction valued at $340 million. — The acquisition expands ResMed's product ecosystem into neuromodulation for RLS, representing a material strategic expansion and capital outlay.
+0.40ResMed will integrate Noctrix Health's FDA-authorized non-invasive therapy, Nidra, into its sleep health ecosystem. — Adding a first-in-class, FDA-authorized therapy for Restless Legs Syndrome provides a new revenue stream and competitive advantage in the sleep health market.
+0.30Angelini Ventures has achieved its first portfolio company exit through the sale of Noctrix Health. — While a positive validation of the venture firm's strategy, this is a private equity event with minimal impact on broader public markets.
+0.10Ticker attribution
Continue reading
6 related stories
Model heads
The company is expanding its sleep health ecosystem by acquiring Noctrix Health, providing it with a first-in-class therapy for Restless Legs Syndrome.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Reuters
48m ago
